CureVac’s vaccine proves to have a 47% efficacy rating after its preliminary results

EUROPE – The German company CureVac provided disappointing preliminary results from a clinical trial of its COVID-19 vaccine, dimming hopes that it could help fill the world’s current greatest need. The trial, which included 40,000 volunteers in Latin America and Europe, estimated that CureVac’s mRNA vaccine had an efficacy of just 47 percent, among the lowest reported so far from any COVID-19 vaccine maker. Results released were based on data from 135 volunteers who got sick with COVID-19 as an independent panel compared the number of sick people who had…

Read More

Serum Institute to introduce Novavax’s vaccine in India by September

INDIA – The Indian government through the Serum Institute of India (SII) is planning to introduce an Indian version of Covavax originally formulated by a US based biotech company, Novavax Inc. Clinical trials are underway in India and the vaccine is likely to hit the market under the name Covavax by September this year though clinical trials on children are expected to kick-off from July. The vaccine is among the first to have undergone phase 3 clinical trials at a time when new Covid-19 variants of concern such as the…

Read More

Saudi Arabia’s Tabuk Pharmaceutical inks deal with Moderna to sell Covid-19 shots

DUBAI – Moderna and Tabuk Pharmaceutical Manufacturing Company, a fully owned subsidiary of Astra Industrial Group, a leading Saudi pharmaceuticals company, have announced a three-year partnership to commercialize the Moderna COVID-19 Vaccine and future variant-specific booster candidates in Saudi Arabia. Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorization for the Moderna COVID-19 vaccine in Saudi Arabia. The contract, which is renewable, allows Tabuk the possibility to discuss opportunities to distribute other Moderna mRNA products if authorized in the future. “We appreciate the collaboration of Tabuk…

Read More

Moderna seeks full FDA approval for its Covid vaccine in a bid to reinforce fight against Covid-19

U.S – Moderna has applied for full approval of its Covid vaccine, a move that will see the drug maker attain rights to market the shots directly to consumers. The Moderna vaccine was granted emergency use approval by the FDA in December. The application by Moderna follows Pfizer’s application to have their vaccine granted a biologics license for use in people 16 and older in the U.S. Emergency use approval gives conditional approval based on two months of safety data whereas a biologics license application or a request for full…

Read More

CDC study shows mRNA COVID-19 vaccines are 94% effective in health care personnel

U.S – New C0VID-19 vaccines effectiveness study conducted by CDC shows that mRNA vaccines by Pfizer-Biotech and Moderna reduce ri According to the study, the FDA approved vaccines reduced the risk of contracting SARS-CoV-2 virus by 94% among health care workers who were fully vaccinated. This study is the largest one to date, covering a sample size distribution of 500,000 health care personnel across 25 U.S. states, provides concrete evidence that C0VID-19 vaccines are performing as expected in the real world. Compared to the earlier study by CDC  on health…

Read More

Moderna says its COVID vaccine is safe and effective in adolescents aged 12 to 17

U.S – Leading pharmaceutical manufacturer Moderna says that clinical trials have proved its COVID shot 100 percent effective and safe for use among teenagers. The company seeks to acquire FDA approval before summer to administer the vaccine. It would be the second Covid-19 vaccine available for the age group if it is authorized for use, in addition to the Pfizer BioNTech vaccine. Moderna CEO Stephane Bancel said that the firm is glad the mRNA-1273 was highly effective at preventing covid amongst adolescents, “we remain committed to doing our part to help…

Read More